Harvard Bioscience (NASDAQ:HBIO) vs. Prenetics Global (NASDAQ:PRE) Head-To-Head Analysis

Prenetics Global (NASDAQ:PRE) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a summary of recent recommendations for Prenetics Global and Harvard Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	0	0	1	0	3.00
Harvard Bioscience	0	0	0	0	N/A

Prenetics Global presently has a consensus target price of $9.00, indicating a potential upside of 94.81%. Given Prenetics Global’s higher possible upside, research analysts clearly believe Prenetics Global is more favorable than Harvard Bioscience.

Earnings & Valuation

This table compares Prenetics Global and Harvard Bioscience”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prenetics Global	$21.74 million	1.94	-$62.72 million	($3.23)	-1.43
Harvard Bioscience	$112.25 million	0.93	-$3.41 million	($0.25)	-9.60

Harvard Bioscience has higher revenue and earnings than Prenetics Global. Harvard Bioscience is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

25.0% of Prenetics Global shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 7.8% of Prenetics Global shares are held by insiders. Comparatively, 9.0% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Prenetics Global and Harvard Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-229.17%	-15.70%	-12.98%
Harvard Bioscience	-10.56%	-2.70%	-1.42%

Risk and Volatility

Prenetics Global has a beta of -0.16, indicating that its stock price is 116% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.

Summary

Harvard Bioscience beats Prenetics Global on 9 of the 12 factors compared between the two stocks.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.

About Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.